Researchers from the University of Tsukuba show that angioimmunoblastic T-cell lymphoma (AITL) is dependent on T-cell receptor (TCR) signaling and that dasatinib, a multi-kinase inhibitor that targets the TCR pathway, may improve treatment outcomes UNIVERSITY OF TSUKUBA Tsukuba, Japan – Angioimmunoblastic T-cell Lymphoma (AITL) is an intractable form of non-Hodgkin lymphoma with a bleak prognosis....